Topic Review
Management of Patients with Lower-Risk Myelodysplastic Neoplasms
Myelodysplastic neoplasms (MDS) are a heterogenous group of clonal hematologic disorders characterized by morphologic dysplasia, ineffective hematopoiesis, and cytopenia. These three developments allow for more tailored therapeutic decision-making in view of the expanding treatment options in MDS. For patients with lower risk MDS, treatment is aimed at improving cytopenias, usually anemia. The approval of luspatercept and decitabine/cedazuridine have added on to the current armamentarium of erythropoietic stimulating agents and lenalidomide (for MDS with isolated deletion 5q). Several newer agents are being evaluated in phase 3 clinical trials for this group of patients, such as imetelstat and oral azacitidine. 
  • 216
  • 18 Jul 2023
Topic Review
Non-Steroid Anti-Inflammatory Drugs/Acetylsalicylic Acid-Associated Gastropathy
Drugs are widely used to treat different diseases in modern medicine, but they are often associated with adverse events. Those located in the gastrointestinal tract are common and often mild, but they can be serious or life-threatening and determine the continuation of treatment. The stomach is often affected not only by drugs taken orally but also by those administered parenterally. The first description of the endoscopic picture of the damage to the gastric mucosa associated with the use of aspirin was published by A. Douthwait and J. Lintoff in 1938.
  • 392
  • 18 Jul 2023
Topic Review
Homologous Recombination Deficiency and Prostate Cancer
Homologous recombination deficiency (HRD) is a term describing tumor phenotypes in which the ability to repair DNA double-strand breaks utilizing the homologous recombination repair (HRR) pathway is lost. Lately, precision medicine has been focusing on targetable mutations, although their frequency in tumors may be very low. The most notable mutations that can be targeted in PCa include gene products that regulate DNA repair through homologous recombination (HR), such as BRCA1, BRCA2, ATM, PALB2, CHEK2 and HOXB13.
  • 261
  • 18 Jul 2023
Topic Review
Sobrerol
Respiratory tract infections (RTIs) are usually characterized by mucus hypersecretion. This condition may worsen and prolong symptoms and signs. For this reason, reducing mucus production and improving mucus removal represent relevant aspects of managing patients with RTIs. In this regard, mucoactive drugs may be effective. Mucoactive agents constitute a large class of compounds characterized by different mechanisms of action. Sobrerol is a monoterpene able to fluidify mucus, increase mucociliary clearance, and exert antioxidant activity. Sobrerol is available in various formulations (granules, syrup, nebulized, and suppository). Sobrerol has been on the market for over 50 years.
  • 430
  • 18 Jul 2023
Topic Review
Small Cell Lung Carcinoma
Small cell lung cancer (SCLC) is an aggressive malignancy characterized by rapid proliferation, early dissemination, acquired therapy resistance, and poor prognosis. Early diagnosis of SCLC is crucial since most patients present with advanced/metastatic disease, limiting the potential for curative treatment. While SCLC exhibits initial responsiveness to chemotherapy and radiotherapy, treatment resistance commonly emerges, leading to a five-year overall survival rate of up to 10%. New effective biomarkers, early detection, and advancements in therapeutic strategies are crucial for improving survival rates and reducing the impact of this devastating disease.
  • 363
  • 18 Jul 2023
Topic Review
Metformin and Resveratrol in Glioblastoma Treatment
Glioblastoma’s poor prognosis calls for the discovery of newer, more efficacious management and treatment methods. Metformin and resveratrol exert anticancer effects on major metabolic pathways in glioblastoma cells, resulting in reduced proliferation, increased apoptosis, and reduced tumor growth and volume. The shown effects suggest that metformin and resveratrol can potentially aid in treating glioblastoma.
  • 257
  • 18 Jul 2023
Topic Review
Early Onset Colorectal Cancer Epidemiology
Early onset colorectal cancer (EOCRC) is defined as CRC diagnosed in individuals younger than 50, which is generally considered the ideal age to start screening programs in the average-risk population. Although the overall incidence of colorectal cancer (CRC) is declining, the number of new diagnoses in patients younger than 50 is alarmingly increasing.
  • 256
  • 18 Jul 2023
Topic Review
Intestinal Tryptophan Metabolism in Inflammatory Bowel Disease
Evidence is emerging for the role of intestinal tryptophan metabolism in the development of inflammatory bowel disease (IBD). In order to identify the role of altered intestinal tryptophan metabolism in IBD pathogenesis, a meta-analysis of the transcriptome was performed to identify differentially expressed genes involved in the tryptophan metabolism pathways in intestinal biopsies of IBD as compared to non-IBD controls.
  • 373
  • 18 Jul 2023
Biography
Carlos M. Villalón
Carlos M. Villalón was born in Mexico City on November 2, 1959. He completed his studies in Chemistry & Pharmacy (Pharmacist) in 1983 at the National School of Biological Sciences (IPN), and his postgraduate studies at the Department of Pharmacology and Toxicology of Cinvestav (M.Sc. in 1986 and Ph.D. in 1988). Between 1988 and 1991 he did a postdoctoral stay at the Erasmus Universiteit Rotterd
  • 552
  • 18 Jul 2023
Topic Review
Radiofrequency Ablation in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is responsible for 90% of primary hepatic cancer cases, and its incidence with associated morbidity and mortality is growing worldwide. There are three main types of locoregional therapy: radiofrequency ablation, transarterial chemoembolisation, and transarterial radioembolisation.
  • 273
  • 17 Jul 2023
  • Page
  • of
  • 1352
Video Production Service